Treatment of functional neurological symptoms.

Recruiting

Conditions: functional neurological symptoms
functional somatic symptoms
treatment functional symptoms
randomised controlled trial
Outcome functional neurological symptoms

Registration Number: NL-OMON21971

Lead Sponsor: Academisch Medisch CentrumPostbus 226601100 DD AmsterdamThe Netherlands

Brief Summary: /A

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: Not specified

Target Recruitment: 200

Inclusion Criteria

1. Tension type headache: Headache without alarming symptoms, not consistent with one of the headache syndromes (migraine, cluster headache or analgesic abuse) and at least one other functional symptom;

2. Back and neck pain: Pain not considered to be caused by spinal pathology (fractures, spondylitis, metastases), myelopathy, radiculopathy, plexopathy or neuropathy and at least one other functional symptom;

Exclusion Criteria

1. Patients under 18 years old;

2. Patients known prior to assessment to have psychiatric disorders other than somatoform, depressive, or anxiety disorders;

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary outcome is the patient’s health related quality of life 12 months after randomisation. Health related quality of life will be assessed with using the 'Short Form-36' health survey(SF-36).The primary outcome will be assessed 3, 6 and 12 months after randomisation.

Secondary Outcome Measures

Name	Time	Method
Secondary outcomes are the level of activities of daily living as measured by the 'AMC linear disability scale' (ALDS), self-reported physical symptoms assessed with the somatization subscale of the symptom checklist-90 (SCL-90), symptoms of anxiety and depression assessed by the ‘hospital anxiety and depression scale’ (HADS), pain catastrophizing thoughts assessed with the 'pain catastrophizing scale' (PCS), severity of pain assessed with the 'visual analogue scale' (VAS), absence of work and medical consumption (number of visits to physicians, medical treatments, additional examinations, alternative care). Secondary outcomes will also be assessed at 3, 6 and 12 months.